RadNet (NASDAQ:RDNT – Get Free Report) is one of 233 public companies in the “Healthcare Providers & Services” industry, but how does it weigh in compared to its competitors? We will compare RadNet to similar businesses based on the strength of its earnings, profitability, risk, valuation, institutional ownership, dividends and analyst recommendations.
Valuation & Earnings
This table compares RadNet and its competitors top-line revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| RadNet | $2.38 billion | -$18.65 million | -263.52 |
| RadNet Competitors | $19.18 billion | $301.67 million | -1.70 |
RadNet’s competitors have higher revenue and earnings than RadNet. RadNet is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Profitability
This table compares RadNet and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| RadNet | -0.94% | 3.14% | 1.08% |
| RadNet Competitors | -7.87% | -135.89% | -1.58% |
Institutional and Insider Ownership
77.9% of RadNet shares are owned by institutional investors. Comparatively, 56.7% of shares of all “Healthcare Providers & Services” companies are owned by institutional investors. 5.1% of RadNet shares are owned by insiders. Comparatively, 14.9% of shares of all “Healthcare Providers & Services” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Analyst Recommendations
This is a breakdown of recent ratings and target prices for RadNet and its competitors, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| RadNet | 1 | 1 | 6 | 1 | 2.78 |
| RadNet Competitors | 1879 | 7752 | 13387 | 833 | 2.55 |
RadNet currently has a consensus price target of $89.67, suggesting a potential upside of 17.33%. As a group, “Healthcare Providers & Services” companies have a potential upside of 13.52%. Given RadNet’s stronger consensus rating and higher possible upside, research analysts plainly believe RadNet is more favorable than its competitors.
Risk and Volatility
RadNet has a beta of 1.42, meaning that its share price is 42% more volatile than the S&P 500. Comparatively, RadNet’s competitors have a beta of 0.98, meaning that their average share price is 2% less volatile than the S&P 500.
Summary
RadNet beats its competitors on 9 of the 13 factors compared.
About RadNet
RadNet, Inc. operates outpatient diagnostic imaging centers in the United States. Its centers provide services including magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), mammography, ultrasound, X-ray and nuclear medicine imaging. The company serves patients, physicians and healthcare organizations, with operations across several states, including California, Delaware, Florida, Maryland, New Jersey and New York. Its imaging centers offer diagnostic services for a range of medical needs, from routine screening to specialized examinations.
Receive News & Ratings for RadNet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RadNet and related companies with MarketBeat.com's FREE daily email newsletter.
